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http://dx.doi.org/10.1016/j.ccell.2015.06.003SUMMARYThe genetic programs thatmaintain leukemia stem cell (LSC) self-renewal and oncogenic potential have been
well defined; however, the comprehensive epigenetic landscape that sustains LSC cellular identity and func-
tionality is less well established. We report that LSCs in MLL-associated leukemia reside in an epigenetic
state of relative genome-wide high-level H3K4me3 and low-level H3K79me2. LSC differentiation is associ-
ated with reversal of these broad epigenetic profiles, with concomitant downregulation of crucial MLL target
genes and the LSC maintenance transcriptional program that is driven by the loss of H3K4me3, but not
H3K79me2. The H3K4-specific demethylase KDM5B negatively regulates leukemogenesis in murine and hu-
manMLL-rearranged AML cells, demonstrating a crucial role for the H3K4 global methylome in determining
LSC fate.INTRODUCTION
A substantial subset of driver mutations in human cancers tar-
gets a variety of epigenetic regulatory factors, suggesting that
perturbations of the epigenome serve important roles in cancer
pathogenesis. These factors include proteins that place, re-
move, or bind covalent modifications within histones or DNA
and multi-protein complexes that regulate nucleosome position.
Perturbations of these factors contribute to localized epigenetic
alterations that cause aberrant expression of crucial genes that
drive oncogenesis. However, there is much less known about
the global epigenetic landscape of cancer cells, particularly the
epigenomic features that may distinguish cancer stem cells,
the pathologically important subpopulation of cells that sustains
disease and mediates relapse.
Emerging evidence based on analyses of a variety of malig-
nancies suggests that global epigenetic abnormalities may beSignificance
Localized epigenetic alterations serve crucial roles in causing a
oncoproteins; however, much less is known about the global e
nomic features that may functionally distinguish leukemia stem
leukemia cells that sustains disease and mediates relapse. In
H3K4 trimethylation serves amajor role in regulating LSC fate a
by the histone demethylase KDM5B, which functions as a tum
tional program.
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For example, epigenomic analysis of the DNA methylomes in
two molecular subtypes of chronic lymphocytic leukemia (CLL)
showed widespread gene-body DNA hypomethylation when
compared to the respective normal B cell subpopulations (Kulis
et al., 2012). In a study of acute myeloid leukemia (AML) epige-
nomes, an epigenetic signature derived from hundreds of genes
with widespread alteration of histone 3 lysine 9 trimethylation
(H3K9me3) level was associated with patient prognosis, and,
when combined with established clinical prognostic markers,
outperformed prognosis prediction based on clinical parameters
alone (Mu¨ller-Tidow et al., 2010). Large-scale alterations of can-
cer cell epigenomes characterized by distinctive histone modifi-
cations also commonly are seen in other cancer types, including
prostate cancer (Seligson et al., 2005), non-small-cell lung can-
cer (Barle´si et al., 2007), low-grade bladder cancer (Barbisan
et al., 2008), and renal cell carcinoma (Seligson et al., 2009), inberrant regulation of primary target genes for MLL and other
pigenetic landscape of leukemia cells, particularly the epige-
cells (LSCs), the pathologically important subpopulation of
this report the authors demonstrate that the global state of
nd oncogenic potential. Mechanistically, this is orchestrated
or suppressor to extinguish the LSC maintenance transcrip-
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Figure 1. Global Levels of Various Histone
Modifications and RNA Pol II
(A) Comparison of global levels of various histone
marks and RNA Pol II in c-kit+ and c-kit cells
(genomic region3,000 to +7,000 relative to TSS).
Total number of reads is normalized by RPM (reads
per million) for variation between c-kit+ and c-kit
cells. For ease of comparison, RPM is scaled to
100% of c-kit+ for each histone modification or
RNA Pol II.
(B) Whole-genome heatmap view is shown for in-
dividual genes with ChIP read density signal en-
compassing the same genomic region as above.
(C) Western blot analysis was performed on acidic
extracted histone proteins of c-kit+ and c-kit
AML subpopulations for the indicated histone
modifications.
See also Figure S1 and Table S1.addition to AML (Yamazaki et al., 2013). Broad DNA hypomethy-
lation is present in a variety of cancer types (Kulis and Esteller,
2010). However, it is unclear whether these genome-wide epige-
netic features, which are typically measured in bulk tumor cell
populations or partially enriched phenotypic subpopulations,
are also a feature of rare cancer stem cells or mechanistically
related to their maintenance or differentiation. Therefore, the
functional epigenomes of cancer stem cells are generally
unknown, and their delineation is compromised by low stem
cell prevalence.
Previous studies (Krivtsov et al., 2006; Somervaille and
Cleary, 2006) have shown that AMLs induced by MLL onco-
genes are organized in a cellular hierarchy, whose apex is
comprised of a minor fraction of phenotypically distinct progen-
itor-like leukemia stem cells (LSCs) with self-renewal capability
and the potential to differentiate into non-self-renewing progeny
cells that constitute the vast majority of the leukemia clone. The
ability to enrich for LSCs allowed the demonstration that LSC
differentiation and loss of self-renewal is associated with the
differential expression of several thousand genes (Somervaille
et al., 2009). Our study was conducted to interrogate the
epigenetic landscape of LSCs underlying these broad gene
expression changes and determine its role in maintaining LSC
oncogenic potential.
RESULTS
LSCs Are Maintained in an H3K4 Hypermethylation and
H3K79 Hypomethylation Epigenetic State
To initially interrogate the LSC epigenome, we employed a retro-
viral transduction/transplantation model of AML induced by the
MLL-AF10 oncogene (Figures S1A–S1D). In this model, AML
cells form a well-defined hierarchy in which subpopulations en-
riched or depleted for LSCs are distinguished by the presence
or absence of c-kit expression, respectively (Somervaille andCancer Cell 28, 198–209Cleary, 2006). Clonogenic activity in
methylcellulosemedium, which is a surro-
gate marker of LSC potential in this
model, showed that LSCs comprised
approximately one-quarter of the c-kit+subpopulation and were 25-fold more prevalent compared to
the more differentiated c-kit cells.
Chromatin immunoprecipitation sequencing (ChIP-seq) was
performed on the two AML subpopulations using antibodies
specific for various histone modifications. Bound DNA regions
(ChIP peaks/region) that passed statistical significance were
mapped to the genome using a peak-calling algorithm (Table
S1). Global read density profiles showed that transcription acti-
vation-associated epigenetic marks (H3K4me2, H3K4me3,
H3K18ac, and H3K27ac) and the repressive H3K27me3 mark
generally were located near the transcription start site (TSS),
whereas elongation marks (H3K36me3 and H3K79me2) were
distributed predominantly along gene bodies (at significant false
discovery rate [FDR] value, Table S1; Guenther et al., 2007).
Assessment of the normalized global ChIP-seq read densities
(RPM, reads per million) showedmarked differences in the quan-
titative levels of H3K4 and H3K79 methylation marks in the
defined genomic regions (3 kb upstream and 7 kb downstream
of TSS) in c-kit+ versus c-kit cells (Figure 1A). H3K4me2 and
H3K4me3 were 60% higher in c-kit+ cells compared to c-kit
cells. Conversely, the level of H3K79me2 was approximately
40% lower in c-kit+ cells. All other histone marks were quantita-
tively similar between the two subpopulations.
To interrogate the genomic distribution of the observed differ-
ences in histone marks, the ChIP-seq signal in the defined
genomic compartment of each individual gene was calculated
and plotted as a heatmap value on a whole-genome view (Fig-
ure 1B; Figure S1E). This showed that H3K4 methylation in
c-kit+ cells was distributed broadly throughout the genome,
and its global reduction in c-kit cells was not restricted to genes
in a specific chromosomal region. H3K79me2 showed an inverse
profile with genome-wide quantitative increase from relatively
lower levels in c-kit+ to higher levels in c-kit cells. All other
assessed histone marks (H3K18ac, H3K27ac, H3K36me3, and
H3K27me3) based on normalized ChIP-seq signals were evenly, August 10, 2015 ª2015 Elsevier Inc. 199
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Figure 2. Presence of Various HistoneMod-
ifications and RNA Pol II on Differentially
Expressed Genes
Normalized ChIP-binding regions are displayed for
various histone modifications and RNA Pol II on
the Kit,Hmgb1, andMyb genes in c-kit+ and c-kit
cells. The y axis scale represents normalized read
density where c-kit+ and c-kit cells for individual
histone marks use the same scale.
See also Figure S2.distributed between c-kit+ and c-kit cells. Western blot analysis
of acid-extracted nuclear histones confirmed increased total
relative levels of H3K4me2/3 and reduced H3K79me2 in c-kit+
versus c-kit cells (Figure 1C), as also was demonstrated by
M-A plot analyses (Figure S1F). Thus, c-kit+ cells enriched for
LSCs are maintained in a global epigenetic state characterized
by relative H3K4 hypermethylation and H3K79 hypomethylation.
Notably, differentiation of LSCs is associated with inversion
of this global epigenetic profile, with a broad decrease of
H3K4me2/3 and an increase of H3K79me2.
H3K4 Methylation Levels Exclusively Correlate with
Differential Expression of MLL Target Genes and LSC
Maintenance Genes
Given the differences in global H3K4 andH3K79methylation that
distinguish c-kit+ cells enriched for LSCs compared to c-kit
cells, we investigated the local histone marks on Hoxa9 and
Meis1, which are direct targets of MLL oncoproteins required
for AML pathogenesis. Analysis of ChIP-seq read densities
showed that Hoxa9 was occupied by activation and elongation
histone marks (except H3K36me3), which displayed a broad dis-
tribution throughout the adjacent Hoxa gene cluster in both pop-
ulations (Figure S2). Meis1 also was occupied by active histone
marks, including elongation marks, which were distributed
throughout the full gene body (Figure S2). The histone marks
that most closely correlated with Hoxa and Meis1 expression
in the c-kit+ versus c-kit populations were H3K4me2 and
H3K4me3, which were reduced about 40% in the c-kit LSC-
depleted population, consistent with comparably lower tran-
script levels (Somervaille et al., 2009). H3K79 dimethylation
showed anomalous features in both AML subpopulations. It
was broadly distributed through the Hoxa and Meis1 genes,
and its abundance in c-kit+ cells contrasted with the low global200 Cancer Cell 28, 198–209, August 10, 2015 ª2015 Elsevier Inc.background levels of H3K79me2, but
was consistent with that previously
observed in bulk MLL leukemia cells
(Bernt et al., 2011), likely reflecting aber-
rant recruitment of the DOT1L histone
methyltransferase by MLL-AF10 to its
target genes. The c-kit population unex-
pectedly showed increased occupancy
of H3K79me2 (31% for Hoxa9 and 16%
for Meis1), which was consistent with
increased global background levels, but
indicated that reduced Hoxa and Meis1
expression in c-kit cells was not caused
by reduced H3K79 methylation levels.We also examined the histone marks on genes (Hmgb1 and
Myb) previously demonstrated to be differentially expressed in
c-kit+ cells and to serve crucial roles in maintaining LSC potential
by preventing terminal differentiation (Somervaille et al., 2009).
Notably, only H3K4me2/3 marks displayed major variation in
density on these genes in the c-kit+ versus c-kit subpopulations
(Figure 2). Most other marks demonstrated minimal variation
except moderately higher H3K36me3 in c-kit+ cells. The repres-
sive H3K27me3 mark was not present on either gene despite
their transcriptional downregulation. These epigenetic profiles
contrasted with those observed on Kit, whose differentially
expressed product served as a cell surface marker for isolation
of LSCs. Kit displayed a more conventional epigenetic profile
wherein all active histone marks present in c-kit+ cells
were erased in c-kit cells and replaced with the repressive
H3K27me3 mark.
A substantial reduction of H3K4me marks in c-kit versus
c-kit+ cells affected almost all genes of the broader LSC mainte-
nance program (190 genes) (Somervaille et al., 2009), as por-
trayed in a heatmap of mark densities (Figure 3A). Conversely,
H3K79me2 levels on these genes were high in c-kit+ cells
compared to the low global background levels and remained
relatively high in c-kit cells, suggesting that loss of this mark
did not participate in extinguishing the LSC maintenance pro-
gram to promote LSC terminal differentiation. Assessment of
all genes significantly downregulated in c-kit versus c-kit+ cells
showed a similar H3K4me3 reduction as observed for the LSC
maintenance program (Figure 3B), suggesting that global
erasure of H3K4me3 was linked to transcriptional downregula-
tion associated with leukemia cell differentiation.
Gene set enrichment analysis (GSEA) confirmed that genes
comprising the LSCmaintenance signature were highly enriched
for differential H3K4me3 levels in c-kit+ versus c-kit cells
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Figure 3. The LSC-Positive Maintenance Transcriptional Program Is
Sustained by Hypermethylation of H3K4me3
(A) Heatmap displays the densities of histone modification marks and RNA Pol
II on genes (190) that comprise the LSC-positive maintenance transcriptional
program. The ChIP signal density was calculated for full gene length (TSS to
gene end) and normalized per total number of reads and per 1 kb of gene
length.
(B) Heatmap displays the H3K4me3 and H3K79me2 histonemodification mark
densities on all genes significantly upregulated in c-kit+ cells, as quantified and
normalized in (A).
(C) Gene set enrichment analysis (GSEA) plots showing the LSC-positive
maintenance program and the ESC-like transcriptional program in genes
marked by H3K4me3 in c-kit+ versus c-kit cells. The dataset represents the
rank-ordered RefSeq genes with H3K4me3 density ratios in c-kit+ versus
c-kit cells.(Figure 3C). Enrichment also was observed for genes encoding
an embryonic stem cell-like program driven by MYC and impli-
cated in LSC maintenance. Thus, c-kit+ cells are maintained in
a global hypermethylated H3K4 epigenetic state that sustains
the LSC maintenance transcriptional program and the expres-
sion of Hoxa and Meis1 genes. Reduced H3K4 methylation is
the major epigenetic alteration that correlates with downregula-
tion of the LSC transcriptional program, raising the possibility
that global modulation of this mark serves a mechanistic role in
LSC maintenance.
Histone Demethylase KDM5B Negatively Regulates LSC
Oncogenic Potential
The dynamic changes of the epigenomes in the two AML sub-
populations raised the possibility that differential expression ofspecific writers or erasers of H3K4 methylation marks may regu-
late LSC potential. Microarray data from published studies
(Somervaille et al., 2009) showed that transcript levels of the
MLL/SET1 family of HMTs that catalyze H3K4 methylation
were not relatively higher in the LSC-enriched subpopulations
(Figure S3A). However, transcript levels for Kdm5b, which
encodes a member of the KDM5 family of H3K4 histone deme-
thylases, were several-fold higher in c-kit compared with
c-kit+ AML cells (Figures S3B and S3C). Kdm5b transcripts
were also substantially higher in normal differentiated neutro-
phils compared with bonemarrow (BM) cells (Figure S3D). These
findings raised the possibility that programmed upregulation of
KDM5B may extinguish LSC potential by reducing H3K4me2/3
levels on Hox/Meis and LSC maintenance genes.
In support of this possibility, ectopic overexpression of
KDM5B (Figure 4A) reduced Hoxa9 and Meis1 transcript levels
(Figure S3E) and markedly suppressed the in vitro growth of
MLL-AF9-transduced cells and MLL-AF10 leukemia cells (Fig-
ures 4B–4D). Compared with control cells, colony numbers
were substantially reduced and colonies appeared less compact
and smaller in size. Cells transformed by non-MLL oncogenes
were not significantly affected by forced KDM5B expression,
suggesting that the negative effect of KDM5B may be relatively
specific to MLL leukemia cells. KDM5B substantially impaired
proliferation in liquid culture (Figure 4C) and inducedmorpholog-
ical differentiation (Figure 4E). The suppressive effects of
KDM5B on colony-forming cell (CFC) potential and H3K4me3
levels were dependent on its catalytic activity (Figures S3F and
S3G). Western blot analysis confirmed that the forced KDM5B
expression reduced global levels of H3K4me3 in MLL-trans-
formed and control cells (Figure 4F; Figures S3H and S3I).
ChIP analysis of MLL-AF10 AML cells demonstrated that most
of the top 46 differentially expressed genes comprising the
LSC maintenance program displayed reduced H3K4me3 levels
and increased KDM5B occupancy that generally correlated
with reduced transcript levels in response to forced KDM5B
expression (Figures 4G and 4H). Transplantation of KDM5B-
overexpressing cells into syngeneic recipient mice showed a
marked reduction in leukemia penetrance and increased survival
compared with vector control cells (Figures 4I and 4J). Limit-
dilution secondary transplantation assays showed that the LSC
frequency in MLL-AF10 AML was reduced more than 15-fold in
response to KDM5B overexpression (Figure 4K). Thus, KDM5B
suppresses leukemogenesis and forces AML cells to differen-
tiate out of the LSC compartment.
Knockdown of KDM5B had the opposite effects on MLL-
transformed cells. In methylcellulose assays, reduced levels of
KDM5B (Figure 5A) caused a significant increase in colonies
that were substantially larger and more densely compact, indi-
cating that they contained increased numbers of progenitors
impaired in their differentiation (Figures 5B and 5C). KDM5B
knockdown was associated with increased levels of H3K4me3,
both globally (Figure 5D) and more specifically on the top 46
genes of the LSC program, which showed concomitant
increases in their transcript levels (Figure 5E). A substantial
enhancement in leukemia aggressiveness was observed
following transplantation of KDM5B-knockdown MLL-AF10
cells, as evidenced by a significantly decreased latency for
AML development (Figure 5F). These data support a tumorCancer Cell 28, 198–209, August 10, 2015 ª2015 Elsevier Inc. 201
Figure 4. KDM5B Reduces Global H3K4me2/3 Methylation and Suppresses AML
(A) Bar graph shows Kdm5b transcript levels in transformed cells (denoted below) transduced with the indicated KDM5B overexpression or control MT (empty)
vectors. Transcript levels were quantified by RT-PCR at 2 days and expressed relative to control vector.
(B and C) Growth in methylcellulose (B) or liquid (C) culture was quantified after exogenous overexpression of KDM5B in cells transformed by the indicated
oncogenes. Colony counts are expressed relative to empty vector (MT)-transduced control cells.
(D) Representative colonies are shown for the experiment in (B). Scale bar represents 20 mm.
(E) Light microscopy of May-Grunwald/Giemsa-stained leukemia cells after transduction with KDM5B overexpression constructs. Scale bar represents 10 mm.
(F) Western blot analysis was performed using the antibodies indicated on the left to assess global histone modification levels following exogenous over-
expression of KDM5B and empty vector (MT).
(G) Scatterplot is shown for H3K4me3 andmRNA expression levels on 46 genes in the LSC programofMLL-AF10 AML cells transducedwith control empty vector
(MT) or KDM5B overexpression constructs. Correlation is indicated as R2 value.
(legend continued on next page)
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Figure 5. Knockdown of KDM5B Promotes AML and LSC Potential
(A) Bar graph indicates Kdm5b transcript levels in cells transduced with the indicated shRNAs. Transcript levels were quantified by RT-PCR at 2 days and
expressed relative to control vector.
(B) Growth in methylcellulose culture was quantified after shRNA knockdown of KDM5B in cells transformed by the indicated oncogenes. Results are expressed
relative to control shRNA-transduced cells.
(C) Representative colonies are shown for the experiment in (B). Scale bar represents 50 mm.
(D) Western blot analysis was performed using the antibodies indicated on the left to assess global histone modification levels following knockdown of KDM5B.
(E) Scatterplot is shown for H3K4me3 and mRNA expression levels on 46 genes in the LSC program in MLL-AF10 AML cells transduced with control or Kdm5b
shRNA constructs. Their correlation is indicated as R2 value.
(F) Survival curves are shown for cohorts of mice transplanted withMLL-AF10 AML cells transducedwith control orKdm5b shRNA constructs (n = 5 each cohort).
Acute leukemia was confirmed by peripheral blood leukocyte count or necropsy. Log-rank test was used for statistical analysis (p = 0.0025).
Error bars represent SEM.suppressor role for KDM5B, and modulation of its expression to
perturb the epigenome in MLL leukemias demonstrates the
importance of H3K4 methylation levels in maintaining LSC
potential.
Histone Demethylase KDM5B Negatively Regulates
Human MLL Leukemia Cells
A similar approach was employed to investigate whether the
H3K4 epigenome serves an analogous role in sustaining onco-
genic potential of human MLL-rearranged (MLLr) leukemias.
KDM5B was knocked down in various human leukemia cell lines
harboring several different MLL fusion genes, including THP-1
(MLL-AF9), Monomac-6 (MLL-AF9), MV4-11 (MLL-AF4), ML-2
(MLL-AF6), and HB (MLL-ENL), as well as the non-MLLr leuke-
mia cell line K562. In MLLr leukemias, an 80% knockdown of
KDM5B induced a significant increase in blast-like colonies
that were substantially larger and more densely compacted(H) Scatterplot is shown for H3K4me3 and KDM5B occupancy levels on 46 gene
KDM5B overexpression constructs. Correlation is indicated as R2 value.
(I and J) Survival curves are shown for cohorts of mice transplanted with MLL-A
KDM5B overexpression constructs (n = 5 each cohort). Acute leukemia was confi
for statistical analysis.
(K) Limit-dilution transplantation analyses performed on MLL-AF10 leukemia cel
cell numbers required to initiate AML in sublethally irradiated recipient mice (n =
Error bars represent SEM.
See also Figure S3.compared to controls, consistent with the presence of increased
numbers of progenitors with impaired differentiation (Figures
6A–6C). In contrast, K562 cells were not affected (Figure S4A).
Knockdown MLLr leukemia cells also proliferated faster (less
so for MV4-11) in liquid culture (Figure 6D), further indicating
that KDM5B normally serves a leukemia-suppressive role.
Consistent with this, forced expression of KDM5B (fused with
GFP to provide a selectable marker) reduced colony formation
in MLLr leukemia cells (Figures 6E and 6F), and the remaining
colonies appeared smaller with more differentiated morphol-
ogies compared to controls (Figure 6G). Non-MLLr cells (K562,
Kasumi-1, and HL-60) did not show reductions in colony
numbers following KDM5B overexpression (Figures 6F and 6G;
Figures S4B and S4C). HOXA9 and MEIS1 gene transcripts
and their H3K4me3 levels were significantly reduced only in
MLLr leukemia cells following KDM5B overexpression despite
a global reduction in H3K4me3 levels (Figures S4D–S4F), whichs in the LSC program of MLL-AF10 AML cells transduced with control (MT) or
F9-transformed cells (I) or MLL-AF10 AML cells (J) transduced with control or
rmed by peripheral blood leukocyte count or necropsy. Log-rank test was used
ls transduced with control (MT) or KDM5B overexpression constructs indicate
3 for each cell dose).
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Figure 6. KDM5B Regulates the Oncogenic Potential of Human MLL Leukemia Cells
(A) Bar graph indicates KDM5B transcript levels in cells transduced with the indicated shRNAs. Transcript levels were quantified by RT-PCR at 2 days and
expressed relative to control vector.
(B) Growth in methylcellulose was quantified after shRNA knockdown of KDM5B in the indicated human leukemia cell lines. Colony counts are expressed relative
to those of control shRNA.
(C) Representative colonies are shown for the experiment in (B). Scale bar represents 20 mm.
(D) Proliferation in liquid culture was measured after shRNA knockdown of KDM5B in the indicated human leukemia cell lines.
(E) Bar graph indicates KDM5B transcript levels in cells transduced with KDM5B overexpression or control empty (MT) vectors. Transcript levels were quantified
by RT-PCR at 2 days and expressed relative to control vector.
(F) Growth in methylcellulose was quantified after exogenous overexpression of KDM5B in the indicated human leukemia cell lines. Colony counts are expressed
relative to those of vector control.
(G) Representative colonies are shown for the experiment in (F). Scale bar represents 20 mm.
(H and I) In vivo engraftment assay shows the relative abundance of MV4-11 cells transduced with KDM5B knockdown (H) or overexpression (I) lentiviral
constructs in the BM at 2 weeks post-transplantation. Results represent the percentage of transduced cells (mCherry or GFP positive) within the total CD45+
population and are expressed relative to the percentage in the input population immediately prior to transplantation (*p < 0.01).
(J) Western blot analysis shows H3K4me3 levels in flow-sorted transduced MV4-11 cells following KDM5B knockdown (mCherry+ cells) or overexpression (GFP+
cells).
Error bars represent SEM.
See also Figure S4.
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Figure 7. KDM5B Suppresses the Oncogenic Potential of Human MLLr AML
(A) Flow cytometry analysis shows CD34 and CD38 expression by a representative human MLLr AML.
(B) KDM5B transcript levels were quantified by RT-PCR analysis of flow-sorted MLLr AML cells with the indicated CD34/CD38 phenotypes. Results are
expressed relative to levels in the CD34+CD38+ population and represent the mean and SEM of three replicates.
(C) Bar graph indicates growth inmethylcellulose culture ofMLLr AML cells transduced with KDM5B or lentiviral empty vector (MT) control. Results are expressed
relative to empty vector control cells.
(D) Representative colonies are shown for the experiment in (C). Scale bar represents 100 mm.
(E) In vivo engraftment assay shows the relative abundance of two primary MLLr AMLs transduced with KDM5B overexpression lentiviral constructs in the BM at
8 weeks post-transplantation. Results represent the percentage of transduced cells (GFP+) within the total CD45+ population and are expressed relative to the
percentage in the input population immediately prior to transplantation (*p < 0.01).
Error bars represent SEM.partly explains the selective effect of KDM5B in MLLr leukemia
cells.
Xenotransplantation studies showed that knockdown of
KDM5B enhanced BM engraftment efficiency of MV4-11 cells
in NSG mice by about 40% compared to control (sh-LUC) cells
(Figure 6H), whereas overexpression of KDM5B substantially
impaired engraftment (Figure 6I) at 2 weeks. Western blot anal-
ysis of transduced cells sorted via fluorescence-activated cell
sorting (FACS) prior to transplant confirmed the respective
increase and decrease of global H3K4me3 levels in KDM5B
knockdown and overexpression cells (Figure 6J).
KDM5B Suppresses LSC Activity in Human MLLr AML
The role of KDM5B was assessed in primary human AML,
wherein LSCs are typically enriched in the CD34+ compartment
including the CD34+CD38 and CD34+CD38+ subfractions
(Eppert et al., 2011). We first compared KDM5B expression in
prospectively purified LSC-enriched (CD34+CD38+) and LSC-
depleted (CD34CD38) MLLr AML subpopulations (Figure 7A),
which showed KDM5B upregulation in the more-differentiated
double-negative cells consistent with a tumor-suppressive role
in human AML (Figure 7B). In support of this, primary MLLr
AML cells transduced with a KDM5B overexpression lentivirus
formed significantly fewer colonies and their morphology ap-
peared less compact and more differentiated than the blast-
type colonies prevalent in the vector control culture (Figures
7C and 7D). In addition, xenotransplantation studies of two pri-mary MLLr AMLs showed that enforced expression of KDM5B
substantially reduced BM engraftment efficiency in NSG mice
compared to controls (empty vector) (Figure 7E). These results
support that histone demethylase KDM5B negatively regulates
the oncogenic potential of human MLLr leukemia cells, analo-
gous to its role observed in mouse LSCs.
DISCUSSION
Genome-wide epigenetic mechanisms are well known to serve
crucial roles in normal stem cell biology. However, a comprehen-
sive analysis of functionally validated cancer stem cell epige-
nomes has been hindered by limited quantities of sufficiently
enriched stem cells to perform similar genome-wide analyses.
Thus, it has been unclear if the epigenomes of cancer stem cells
are distinct from more-differentiated progeny cells in the tumor
that lack stem cell activity, as it also has been unclear whether
the biological properties that define malignant stem cells are
maintained or extinguished by global features of the epigenome.
In this report, we demonstrate that the c-kit+ population of leuke-
mia cells enriched for LSCs (25%) is maintained in a distinctive
epigenomic state that undergoes global change with their sub-
sequent differentiation. The epigenomes of c-kit+ cells share fea-
tures with embryonic stem cells (ESCs) and hematopoietic stem
cells (HSCs), including a major role for the global state of H3K4
trimethylation in regulating LSC fate and oncogenic potential.
Mechanistically, this is orchestrated by the histone demethylaseCancer Cell 28, 198–209, August 10, 2015 ª2015 Elsevier Inc. 205
KDM5B, which functions as a tumor suppressor by downregulat-
ing transcriptional programs that otherwise sustain LSC self-
renewal and leukemogenic function.
H3K4me3 is a functionally important histone mark that is typi-
cally promoter-centric in location, associated with open chro-
matin, and generally present on actively transcribed genes.
Global H3K4 methylation state has been implicated in normal
stem cell functions, particularly the maintenance and differentia-
tion of ESCs (Bernstein et al., 2006; Mikkelsen et al., 2007;
Meissner et al., 2008). Both mouse and human ESCs display
globally more open and dynamic chromatin characterized by
the enrichment of widespread active chromatin domains con-
taining H3K4me3 (Ho and Crabtree, 2010; Meshorer et al.,
2006; Azuara et al., 2006; Lister et al., 2009), and global loss of
H3K4me3 accompanies differentiation of ESCs to progenitor
cells (Efroni et al., 2008).
In HSCs, about two-thirds of genes are occupied by H3K4me3
(Sun et al., 2014; Cui et al., 2009) and, upon induced differentia-
tion, thousands of genes lose this active mark (Cui et al., 2009).
Analysis of chromatin marks in isolated hematopoietic cell sub-
populations (Lara-Astiaso et al., 2014) shows that high global
H3K4me3 undergoes reduction (30%–40%) with the differentia-
tion of HSCs to granulocytes andmonocytes (data not shown). In
addition, enhancement of H3K4me3 on important HSC genes by
knockdown of KDM5B antagonizes HSC differentiation (Cellot
et al., 2013). These findings are consistent with our observations
that KDM5B expression is upregulated with normal myeloid dif-
ferentiation. Similarly, in c-kit+ cells enriched for LSCs, several
thousand genes are differentially expressed upon differentiation,
and over one-third of them are downregulated in parallel with
reduced H3K4me3, suggesting that the LSC transcriptional pro-
gram is epigenetically maintained by H3K4me marks whose
broad reduction induces LSCs to differentiate. These studies
support a model wherein differentiation of both normal hemato-
poietic cells and AML cells is accompanied by a programmed
reduction of global H3K4 methylation. This differentiation-linked
epigenetic program antagonizes LSC oncogenic (and HSC) po-
tential, but is opposed by MLL oncoproteins with which it com-
petes. MLLr leukemias are highly sensitive to alterations in the
H3K4 methylome, since the MLL-specific gene program is inor-
dinately dependent on H3K4 methylation status (particularly key
target genes such as HOXA9 and MEIS1 whose expression is
normally maintained by wild-type [WT] MLL, an H3K4 methyl-
transferase that also is required for MLL-mediated transforma-
tion [Thiel et al., 2010]), likely contributing to the selective role
of H3K4me in this genetic subtype of AML compared with non-
MLLr AML. Thus, LSC differentiation shares epigenetic features
with normal stem cells, wherein broad reduction of H3K4methyl-
ation extinguishes the HSC program and serves as a primary
oncogenic off switch to downregulate the LSC program in
MLLr leukemia cells.
Our study demonstrates that the histone demethylase KDM5B
is anegative regulator of theoncogenic state through itseffects on
the crucial effector genes that otherwise sustain LSC potential in
AML. This is consistent with recent studies that chromatin regula-
tors may modulate transcriptional responses underlying cell fate
decisions and cellular differentiation and in maintaining the iden-
tity of differentiated cells (Chen and Dent, 2014). KDM5B specif-
ically demethylatesH3K4me1/2/3 (Yamaneet al., 2007;Pedersen206 Cancer Cell 28, 198–209, August 10, 2015 ª2015 Elsevier Inc.and Helin, 2010). It is essential for early embryonic development
(Catchpole et al., 2011) and important for ESC differentiation.
KDM5B depletion has been shown to block differentiation along
the neural lineage due to increased global H3K4me3 levels and
consequent failure to efficiently silence stem- and germ-cell-
related genes (Schmitz et al., 2011). Depletion of KDM5B also im-
pairs ESC differentiation to embryoid bodies, causing partial
retention in a self-renewing stage (Kidder et al., 2013). These
studies are consistent with our observations that KDM5B deple-
tionantagonizes leukemiacell differentiation, upregulatesexpres-
sion of LSC maintenance genes, and substantially enhances the
malignant phenotypes of mouse and human leukemia cells.
LSCs are maintained in a state of high global H3K4 methylation
and low KDM5B expression, whereas upregulation of KDM5B in-
duces leukemia cell differentiation, concomitant loss of LSC fate,
anddownregulation of leukemiamaintenancegenes andkeyMLL
target genes.
The function of KDM5B as a suppressor of MLL leukemia con-
trasts with its potential role in other cancer types, where it is in-
ferred to have oncogenic activity based primarily on elevated
levels of expression in several solid cancers, including breast
(Lu et al., 1999), prostate (Xiang et al., 2007), and bladder (Hay-
ami et al., 2010). Conversely, KDM5B underexpression in an
aggressive subtype of breast cancer (Yamane et al., 2007) and
primary melanoma is consistent with a possible tumor-suppres-
sive function (Roesch et al., 2008). In melanoma, high-level
KDM5B expression in a subpopulation of slow-cycling cells
that maintain a high proliferative population suggested a poten-
tial oncogenic role in cancer stem cells (Roesch et al., 2010).
Taken together, the expression profiles of KDM5B suggest that
its specific oncogenic contributions may be context dependent.
However, our study raises caution about assigning a functional
role for KDM5B or other epigenetic factors based on expression
in bulk tumor cell populations where cancer stem cell-specific
attributes may be obscured. Through analysis of enriched AML
subpopulations, our study reveals a dynamic expression profile
within the leukemia cell hierarchy wherein high-level KDM5B
expression in the majority of leukemia cells is not oncogenic,
but rather mediates a tumor-suppressive function promoting dif-
ferentiation by extinguishing the transcriptional program that
otherwise sustains LSC potential.
In addition to a functionally dynamic H3K4 methylome in MLL
leukemia, c-kit+ LSC-enriched cells display low levels of global
H3K79 methylation, which convert to higher levels in the LSC-
depleted subpopulation. H3K79me2 is a crucial epigenetic
mark required for leukemogenesis induced by MLL fusion pro-
teins, which recruit DOT1L, the methyltransferase that writes
the H3K79me2 mark, and other elongation factors to deregulate
expression of key MLL target genes (Okada et al., 2005; Krivtsov
et al., 2008). Our finding of high H3K79me2 occupancy onHoxa9
and Meis1 genes in the context of low background levels is
consistent with previous observations in bulk MLL leukemia cells
(Bernt et al., 2011), and reinforces the role of its aberrant depo-
sition on MLL target genes in leukemia pathogenesis. The in-
crease in H3K79me2 on MLL target and LSC maintenance
genes in the LSC-depleted population is unexpected, since it
runs counter to their reduced expression and loss of LSC poten-
tial during AML cell terminal differentiation. However, the effects
of increased H3K79me2, an elongation mark, on target gene
expression may be negated by concomitant loss of H3K4me3,
an upstream initiation mark. The differences in genome-wide
H3K79 methylation are not likely caused by differences in
steady-state levels of DOT1L, based on comparable transcript
levels (data not shown), but a potential role for suppressed de-
methylation cannot be excluded, since a specific H3K79 deme-
thylase has not been identified. Alternatively, global H3K79me2
levels may reflect the relative function and/or abundance of
WT AF10 given its role in DOT1L recruitment and stimulation
(Deshpande et al., 2014). Although the mechanism underlying
increased global levels of H3K79me2 in MLLr c-kit cells is un-
clear, relatively high levels of this mark in the LSC-depleted sub-
population correlate with higher global levels of the H3K36me3
elongation mark and Pol II, consistent with increased transcrip-
tion of genes that promote myeloid differentiation. Anti-DOT1L
efficacy with small molecular inhibitor has been observed in pre-
clinical studies (Daigle et al., 2011), indicating that the inhibitory
effects on MLL target gene expression prevail over potential
inhibitory effects on AML cell differentiation. Our study provides
a rationale for an alternative or complementary therapeutic
strategy targeting deposition of H3K4me3, which serves a major
global epigenetic role in sustaining MLL leukemia and LSC
potential.
EXPERIMENTAL PROCEDURES
Cell Culture
Human leukemia cell lines were cultured in RPMI 1640 medium supplemented
with 10% fetal bovine serum (FBS), 13 penicillin/streptomycin/L-glutamine
(PSG), and 13 non-essential amino acid (NEAA). Transformed mouse myeloid
cells or leukemia cells were cultured in RPMI 1640medium supplemented with
20% FBS, 20% WEHI-conditioned medium, and PSG (R20/20 medium), or in
methylcellulose-containingmedium (Methocult M3231, STEMCELL Technolo-
gies) with cytokines as previously described (Lavau et al., 1997). HEK293T and
Phoenix-Eco cells were maintained in DMEM supplemented with 10% FBS
and PSG.
Isolation of Leukemia Cells for ChIP-Seq
Leukemias were induced by retroviral transduction/transplantation of c-kit+
BM stem and progenitor cells with MLL-AF10 as previously described (Som-
ervaille and Cleary, 2006). For ChIP-seq, leukemia cells were collected from
spleens and immediately fractionated based on c-kit expression using
CD117microbeads (130-091-224, Miltenyi Biotec) in an autoMACS, according
to the manufacturer’s protocol. Enrichment of CFCs was quantified by plating
in methylcellulose-containing medium with cytokines (Somervaille and Cleary,
2006). Fractionated cells were fixed at room temperature for 10 min with 0.7%
formaldehyde solution (F8775, Sigma-Aldrich) in R20/20 medium and frozen
at 80C until used for ChIP. All experiments on mice in this study were per-
formed with the approval of, and in accordance with, the Stanford University
Administrative Panel on Laboratory Animal Care.
ChIP-Seq and Bioinformatics Analyses
Fixed leukemia cells were lysed for 20 min in nuclear lysis buffer (50 mM Tris-
HCl [pH 8.0], 10mMEDTA, and 1%SDS) containing freshly added 13 protein-
ase inhibitor cocktail (Roche) on ice, then sonicated to generate DNA frag-
ments of 150–500 bp using a Diagenode Bioruptor XL sonicator for a total
duration of 60 cycles (30 s on and 30 s off). The soluble chromatin was diluted
10-fold with ChIP dilution buffer (20mMTris-HCl [pH 8.0], 150mMNaCl, 2mM
EDTA, 0.01% SDS, and 1% Triton X-100) containing 13 proteinase inhibitor
cocktail, and the diluted chromatin (1 ml equivalent to 2 million cells) was sub-
jected to immunoprecipitation using various ChIP-grade antibodies coupled
with protein A magnetic beads (Invitrogen). After overnight immunoprecipita-
tion at 4C, washes and reverse crosslinking as well as ethanol precipitation
of ChIP DNA were performed by standard ChIP assay protocol. DNA wasused for ChIP-seq library construction based on manufacturer’s protocol,
with modifications to account for the limited number of cells (Schmidt et al.,
2009). Sequencing was carried out at the Stanford Genome Center.
The sequencing reads were mapped to the mouse genome and statistically
confident mapped reads were used for ChIP peak/region calling using Quest
(Valouev et al., 2008) and DNANexus (https://www.dnanexus.com), which
also provided genome browsing. Downstream analysis including genome-
wide localization density plot, chromosome view of global ChIP signal heat-
map, and M-A plot were performed by using a combination of tools including
DNANexus, Seqmonk (http://www.bioinformatics.babraham.ac.uk/), and R
program (R Development Core Team 2012). Some graphs were plotted using
the R program package, ggplot2 (Wickham, 2009). For GSEA of ChIP-seq
data, the ranked genome-wide genes based on their ChIP-seq signal calcu-
lated by normalized ChIP-seq reads on full-length genes were treated as a
dataset for performing enrichment analysis of individual gene sets using
1,000 data permutations.
For standard ChIP assays, chromatin equivalent to 5 million fixed cells was
used for immunoprecipitation. Primers used for target gene detection are pro-
vided in the Supplemental Experimental Procedures.
Leukemogenesis Assays
For overexpression studies, mouse MLL-AF10 leukemia cells or MLL-AF9
immortalized cells were transduced with MSCV-puro retrovirus expressing
full-length mouse KDM5B or empty vector. Transduced cells were cultured
in R20/20 medium for 48 hr, then selected in puromycin for 24 hr prior to trans-
plantation (106 cells) into sublethally irradiated (450 rad) C57BL/6 mice. For
limit-dilution assays, serial dilutions (105, 104, and 0) of MLL-AF10 leukemia
cells transduced with MSCV-KDM5B-puro or empty vector were transplanted
into sublethally irradiated mice. For knockdown studies, mouse MLL-AF10
leukemia cells transduced with pSicoR-mCherry lentivirus expressing small
hairpin RNAs (shRNAs) were cultured 2–3 days in R20/20 before FACS
isolation based on mCherry fluorescence. The sorted mCherry-positive cells
were cultured for several passages before transplantation (1.5 3 106 cells)
into sublethally irradiated recipients.
Viral Vectors and Transduction
The shRNAs were designed using a commercial web tool (Invitrogen) and
consisted of the following: sh-mKDM5B-1 (GCAGTTGTTTGCAAGGATAGA),
sh-mKDM5B-2 (GGGAGTAATTGATTCTGAAAG), sh-hKDM5B-1 (GGAGATG
CACTTCGATATA), and sh-hKDM5B-2 (GCTTCCAAGGCTGATGTATTA). The
shRNAs were cloned into pSicoR-mCherry lentivirus vector. Lentiviruses
were generated by co-transfection of shRNA constructs into HEK293T cells
with pCMV-dR8.2 (packaging) and pCMV-VSVG (envelope) plasmids. Mouse
and human cells were transduced by spinoculation and cultured for 2–3 days
prior to FACS isolation based on mCherry fluorescence. Mouse full-length
Kdm5b cDNA was subcloned into MSCV-puro from pUB6-V5-KDM5B, which
was kindly provided by Dr. Impey (Xie et al., 2011). Retroviral plasmids were
packaged in Phoenix-Eco cells. Viral supernatants were concentrated (at least
10-fold) using retro-x concentrator (Clontech Laboratories) and supplemented
with polybrene for transduction of mouse leukemia cells by spinoculation
(2,500 rpm, 32C for 2.5 hr).
Xenotransplantation Studies
MV4-11 cells were transduced with pSicoR-mCherry encoding KDM5B
shRNAs or GFP-tagged KDM5B cDNA. The percentage of fluorescent cells
was determined at 48 hr by flow cytometry, and three million total cells were
then transplanted into sublethally irradiated (200 rad) NSGmice. Then, 2weeks
later, BM cells were collected and analyzed by flow cytometry for the percent-
age of engrafted human cells (CD45+) expressing the respective fluorescent
marker. Primary human MLLr AML cells (cryopreserved in the Pediatric Cell
Bank at Stanford) were obtainedwith informed consent and institutional review
board approval. Cryopreserved MLL-rearranged primary AML samples were
thawed and cultured in IMDM with 15% FBS supplemented with cytokines
(10 ng/ml hSCF, 10 ng/ml hFlt3, 10 ng/ml hIL-7, 10 ng/ml hIL-3, 10 ng/ml
hIL-6, and 5 ng/ml SR1) for 2 hr. Cells then were transduced with lentivirus
expressing GFP-tagged KDM5B. The percentage of fluorescent cells was
determined 48 hr after transduction, and one million cells were immediately
transplanted into sublethally irradiated (200 rad) NSG mice. Finally, 8 weeksCancer Cell 28, 198–209, August 10, 2015 ª2015 Elsevier Inc. 207
later, BM cells were collected and analyzed by flow cytometry for the percent-
age of engrafted human cells (CD45+) expressing GFP.
Real-Time PCR
RNA was isolated using TRIzol reagent (15596-026, Invitrogen) and con-
verted to cDNA using SuperScript III First-Strand Synthesis System (Life
Technologies). The qPCR analysis was performed using an ABI StepOnePlus
real-time PCR machine. Primers used for SYBR detection are listed in the
Supplemental Experimental Procedures. All signals were quantified using
the DCt method and were normalized to the levels of GAPDH (Gapdh) or
b-actin.
Western Blot Analysis
Western blots for histone modifications were performed on acid-extracted nu-
clear proteins. The following antibodies used for western blot and ChIP assays
were obtained from Abcam: anti-H3K4me2 (ab7766), anti-H3K4me3 (ab8580),
anti-H3K18ac (ab1191), anti-H3K27ac (ab4729), anti-H3K36me3 (ab9050),
anti-H3K79me2 (ab3594), and anti-RNA Pol II (ab817). Anti-H3K27me3 (07-
449) was obtained from Millipore.
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